CGEN
CompugenยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
CGEN Profile
Compugen Ltd.
A developer of Fc fusion therapeutic proteins and mono clonal antibodies for cancer and immune-related disease
Azrieli Center, 26 Harokmim Street, Building D, Holon 5885849 Israel
Focus on the development of therapeutic proteins and monoclonal antibodies.
Compugen Ltd., established on February 10, 1993, is an Israeli company. The company is a clinical-stage therapeutic discovery and development company that leverages widely applicable predictive computational discovery capabilities to identify new drug targets and new biological pathways to develop treatments in the field of cancer immunotherapy. The company's innovative immuno-oncology pipeline consists of three clinical-stage projects, targeting immune checkpoint discoveries by computing COM 701, COM 902 and rilvegostomig. The Company's lead product candidates COM701 (a potential first-in-class anti-PVRIG antibody) and COM902 (a potential best-in-class therapeutic anti-TIGIT antibody) are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors, As a monotherapy and a combination therapy blocked by dual (PVRIG/PD-1, PVRIG/TIGIT) and triple (PVRIG/PD-1/TIGIT).
